Desoxo-narchinol A

Research use only, not for human use.

Desoxo-narchinol A exhibits protective effects against LPS-induced endotoxin shock and inflammation through p38 deactivation, it shows inhibitory activity against LPS-induced NO production. Desoxo-narchinol A shows cytotoxic activity against P-388 cells.

Desoxo-narchinol A exhibits protective effects against LPS-induced endotoxin shock and inflammation through p38 deactivation, it shows inhibitory activity against LPS-induced NO production. Desoxo-narchinol A shows cytotoxic activity against P-388 cells.

Desoxo-narchinol A inhibits tissue injury and production of pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in the liver and lung.Desoxo-narchinol A (0-500 nM, 24 h) inhibits the production of inflammatory mediators, such as iNOS and its derivative NO, COX-2, PGE2, IL-1β, IL-6 and TNF-α and H3 protein acetylation in murine peritoneal macrophages.Desoxo-narchinol A inhibits LPS-induced activation of p38 in murine macrophages.

Desoxo-narchinol A (0-0.5 mg/kg, IP, once) dramatically reduced mortality in a murine LPS-induced endotoxin shock model. Desoxo-narchinol A (50 mg/kg, PO, once) shows the oral bioavailability of 18.1% in rats and 28.4% in mice

——

Others

Other Targets

——

——

——

53859-06-6

192.25

C12H16O2

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years